Market Closed -
Euronext Amsterdam
11:35:13 2024-04-29 EDT
After market
14:48:06
0.905
EUR
+0.56%
0.905
0.00%
Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
December 15, 2022 at 03:22 pm
BlackRock Inc. - Pharming Group N.V. - Leiden
BlackRock Inc. - Pharming Group N.V. - Leiden
Below you will find information from the register substantial holdings and gross short positions. The information has been provided by the organisation.
Date of transaction 14 dec 2022
Person obliged to notify BlackRock Inc.
Issuing institution Pharming Group N.V.
Registration Chamber of Commerce 28048592
Place of residence Leiden
Previous result
Next result
Distribution in numbers
Type of share
Number of shares
Number of voting rights
Capital interest
Voting rights
Manner of disposal
Settlement
Type of share Gewoon aandeel
Number of shares 19.413.374,00
Number of voting rights 19.713.523,00
Capital interest Reëel
Voting rights Reëel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement
Type of share Contract for difference
Number of shares 340.694,00
Number of voting rights 554.703,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement In contanten
Type of share Gewoon aandeel
Number of shares 538.841,00
Number of voting rights 538.841,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement Fysieke levering
Distribution in percentages
Type
Total holding
Directly real
Directly potential
Indirectly real
Indirectly potential
Type Kapitaalbelang
Total holding 3,10 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 2,97 %
Indirectly potential 0,13 %
Type Stemrecht
Total holding 3,18 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 3,01 %
Indirectly potential 0,17 %
Date last update: 15 December 2022
Disclaimer
Pharming Group NV published this content on 14 December 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 15 December 2022 20:22:07 UTC .
Pharming Group to Buy Back EUR123 Million of Bonds due 2025
04-22
MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds
04-18
MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding
04-17
CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
04-08
CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder
04-08
MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024
03-14
CI
Pharming Group Seeks Acquisitions
03-14
CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024
03-14
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
03-14
CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
03-14
CI
RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating
01-09
MT
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies
12-15
CI
Pharming Group Plans Phase 2 Trial for Immune System Drug in 2024
12-13
MT
Pharming Group Plans to Develop Leniolisib for Additional Primary Immunodeficiencies Following Engagement With FDA
12-13
MT
Pharming Group Expects EU Panel Opinion in 2024 for Rare Immunodeficiency Treatment
11-10
MT
Transcript : Pharming Group N.V., Q3 2023 Earnings Call, Oct 26, 2023
23-10-26
Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-26
CI
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director
23-09-25
CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call
23-09-25
ADRs Advance, Warrantee Inc. Climbs 20.0%
23-09-22
DJ
ADRs Close Lower; Quantasing Group Ltd. Declines 33.5%
23-09-21
DJ
Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan
23-08-09
CI
Pharming Seeks Acquisitions
23-08-03
CI
Transcript : Pharming Group N.V., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-03
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
More about the company
Average target price
2
EUR
Spread / Average Target
+122.22%
Consensus
1st Jan change
Capi.
-12.22% 647M +25.92% 661B +26.74% 566B -6.78% 352B +19.10% 332B +3.16% 283B +13.43% 231B +4.71% 200B -9.53% 195B -4.39% 145B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1